Acute Contagious Conjunctivitis

Categories: Eye diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Acute Contagious Conjunctivitis

MalaCards integrated aliases for Acute Contagious Conjunctivitis:

Name: Acute Contagious Conjunctivitis 12 15 70
Pink Eye 12 42 3
Keratoconjunctivitis Due to Mycoplasma Conjunctivae 70
Contagious Opthalmia 12
Conjunctivitis 70
Pinkeye 12


External Ids:

Disease Ontology 12 DOID:11213
NCIt 50 C35704
SNOMED-CT 67 240066005
UMLS 70 C0009763 C1261274 C1313983

Summaries for Acute Contagious Conjunctivitis

MedlinePlus : 42 Conjunctivitis is the medical name for pink eye. It involves inflammation of the outer layer of the eye and inside of the eyelid. It can cause swelling, itching, burning, discharge, and redness. Causes include Bacterial or viral infection Allergies Substances that cause irritation Contact lens products, eye drops, or eye ointments Pink eye usually does not affect vision. Infectious pink eye can easily spread from one person to another. The infection will clear in most cases without medical care, but bacterial pink eye needs treatment with antibiotic eye drops or ointment. NIH: National Eye Institute

MalaCards based summary : Acute Contagious Conjunctivitis, also known as pink eye, is related to albinism, oculocutaneous, type ii and conjunctivitis, and has symptoms including fever, pruritus and bloodshot eye. An important gene associated with Acute Contagious Conjunctivitis is OCA2 (OCA2 Melanosomal Transmembrane Protein), and among its related pathways/superpathways is Melanin biosynthesis. The drugs Pheniramine and Nitrous oxide have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and liver, and related phenotypes are Negative genetic interaction between KRASG13D/+ and KRAS+/- and homeostasis/metabolism

Disease Ontology : 12 A bacterial acute conjunctivitis that is characterized by highly contagious conjunctival hypermia and mucopurulent discharge and has material basis in Hemophilius Aegypticus.

CDC : 3 People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Related Diseases for Acute Contagious Conjunctivitis

Diseases related to Acute Contagious Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 albinism, oculocutaneous, type ii 29.0 TYRP1 TYR SLC45A2 OCA2 HPS5
2 conjunctivitis 11.3
3 agammaglobulinemia, x-linked 11.0
4 kawasaki disease 11.0
5 zika fever 11.0
6 inclusion conjunctivitis 11.0
7 blepharoconjunctivitis 11.0
8 eye disease 11.0
9 measles 11.0
10 muckle-wells syndrome 11.0
11 keratoconjunctivitis 10.3
12 ochronosis 10.2 TYRP1 TYR
13 cataract 18 10.2 TYRP1 OCA2
14 dowling-degos disease 1 10.2 TYRP1 TYR
15 congenital nystagmus 10.1 TYR OCA2
16 amelanotic melanoma 10.1 TYRP1 TYR
17 keratitis, hereditary 10.1
18 chlamydia 10.0
19 ichthyosis, congenital, autosomal recessive 11 10.0 SLC45A2 OCA2
20 tietz albinism-deafness syndrome 10.0 TYRP1 TYR SLC45A2
21 autoimmune disease of skin and connective tissue 9.9 TYRP1 TYR
22 albinism 9.9 TYRP1 TYR SLC45A2 OCA2
23 albinism, oculocutaneous, type v 9.9 TYRP1 TYR SLC45A2 OCA2
24 albinism, oculocutaneous, type ib 9.9 TYRP1 TYR SLC45A2 OCA2
25 albinism, oculocutaneous, type ia 9.9 TYRP1 TYR SLC45A2 OCA2
26 albinism, oculocutaneous, type vii 9.9 TYRP1 TYR SLC45A2 OCA2
27 anisocoria 9.9
28 acute hemorrhagic conjunctivitis 9.9
29 trachoma 9.9
30 fibrosarcoma 9.9
31 nystagmus 6, congenital, x-linked 9.9 TYRP1 TYR SLC45A2 OCA2
32 piebald trait 9.9 TYRP1 TYR SLC45A2 OCA2
33 griscelli syndrome 9.9 TYRP1 TYR SLC45A2 OCA2
34 waardenburg's syndrome 9.9 TYRP1 TYR SLC45A2 OCA2
35 pathologic nystagmus 9.8 TYRP1 TYR SLC45A2 OCA2
36 melanoma, cutaneous malignant 1 9.8 TYRP1 TYR SLC45A2 OCA2
37 skin melanoma 9.8 TYRP1 TYR SLC45A2 OCA2
38 hermansky-pudlak syndrome 1 9.7 SLC45A2 OCA2 HPS5
39 skin carcinoma 9.6 TYRP1 TYR SLC45A2 OCA2
40 albinism, oculocutaneous, type iv 9.5 TYRP1 TYR SLC45A2 OCA2 HPS5
41 albinism, oculocutaneous, type iii 9.5 TYRP1 TYR SLC45A2 OCA2 HPS5
42 ocular albinism 9.4 TYRP1 TYR SLC45A2 OCA2 HPS5
43 oculocutaneous albinism 9.4 TYRP1 TYR SLC45A2 OCA2 HPS5
44 hermansky-pudlak syndrome 9.4 TYRP1 TYR SLC45A2 OCA2 HPS5
45 acute conjunctivitis 8.1 TYRP1 TYR SPSB2 SLC45A2 RPH3AL OCA2

Graphical network of the top 20 diseases related to Acute Contagious Conjunctivitis:

Diseases related to Acute Contagious Conjunctivitis

Symptoms & Phenotypes for Acute Contagious Conjunctivitis

UMLS symptoms related to Acute Contagious Conjunctivitis:

fever; pruritus; bloodshot eye; conjunctival congestion; redness of eye; discharge from eye

GenomeRNAi Phenotypes related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Negative genetic interaction between KRASG13D/+ and KRAS+/- GR00255-A-5 9.02 FAM163A HPS5 KIF22 NT5DC2 TYRP1

MGI Mouse Phenotypes related to Acute Contagious Conjunctivitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.65 BLVRA CST9L FAM163A HPS5 OCA2 RPH3AL
2 pigmentation MP:0001186 9.02 HPS5 OCA2 SLC45A2 TYR TYRP1

Drugs & Therapeutics for Acute Contagious Conjunctivitis

Drugs for Acute Contagious Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 598)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Pheniramine Approved Phase 4 86-21-5 4761
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Ferrous fumarate Approved Phase 4 141-01-5
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
Dipivefrin Approved Phase 4 52365-63-6 3105
Alcaftadine Approved Phase 4 147084-10-4 19371515
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
Montelukast Approved Phase 4 158966-92-8 5281040
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
Fosaprepitant Approved Phase 4 172673-20-0 219090
Insulin lispro Approved Phase 4 133107-64-9
Insulin glargine Approved Phase 4 160337-95-1
Norepinephrine Approved Phase 4 51-41-2 439260
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
Lopinavir Approved Phase 4 192725-17-0 92727
Zidovudine Approved Phase 4 30516-87-1 35370
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
Azathioprine Approved Phase 4 446-86-6 2265
Lithium carbonate Approved Phase 4 554-13-2
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
Rilpivirine Approved Phase 4 500287-72-9 6451164
Didanosine Approved Phase 4 69655-05-6 50599
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
Iloperidone Approved Phase 4 133454-47-4 71360
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741

Interventional clinical trials:

(show top 50) (show all 1021)
# Name Status NCT ID Phase Drugs
1 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
4 Safety and Efficacy of Intranasal Dexmedetomidine as a Sedative in Pediatric Dentistry: a Randomized, Double-blind Clinical Study Unknown status NCT02985697 Phase 4 Dexmedetomidine;Midazolam Hydrochloride;Nitrous Oxide
5 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
6 Prospective, Randomized, Double-blinded, Placebo-controlled Study to Examine Pain Relief and the Need for Supplementary Analgesics With Intra-thecal Morphine Sulfate (0.2 mg) in Patients Undergoing Total Knee Arthroplasty (TKA) Unknown status NCT02620631 Phase 4 Morphine;Placebo
7 Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma Unknown status NCT02277483 Phase 4 LAIS®
8 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
9 Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study Unknown status NCT01167062 Phase 4 Tamsulosin Hydrochloride OCAS 0.4 mg
10 Clinical Outcomes Following Non-Surgical Treatment of Chronic Periodontitis, Using Scaling and Root Planing (SRP) in Conjunction With PerioWave, Compared to SRP Alone Unknown status NCT00296881 Phase 4
11 Transforaminal Epidural Steroid Injection in Conjunction With Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for the Management of Chronic Lumbosacral Radicular Pain: a Randomized, Double-blind Trial Unknown status NCT02930057 Phase 4 Celestone;Control
12 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
13 A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy Unknown status NCT01657812 Phase 4 dexmedetomidine
14 Clinical Trial to Evaluate the Efficacy and Safety of SurgiFill™ on Spinal Fusion -Comparison Between Autograft Mixed With SurgiFill™ and Autograft in Spinal Fusion- Unknown status NCT02466048 Phase 4
15 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Completed NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
16 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Completed NCT01346371 Phase 4 Refresh Tears 0.5% Lubricant Eye Drops;Bepreve 1.5% Ophthalmic Solution
17 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
18 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
19 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
20 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
21 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
22 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
23 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
24 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ® (Placebo)
25 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
26 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
27 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
28 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
29 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
30 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
31 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
32 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
33 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
34 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
35 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
36 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
37 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
38 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
39 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
40 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
41 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
42 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
43 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
44 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
45 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
46 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
47 Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazorac .1% Gel or Vehicle Gel Completed NCT00145106 Phase 4 Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)
48 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
49 Clinical and Radiographic Outcomes of BIO4 Bone Matrix in Patients Undergoing 1 or 2-Level Anterior Cervical Discectomy and Fusion Surgery Completed NCT03077204 Phase 4
50 Twenty-Four-Hour Plasma Glucose Profiles Observed in Patients With Type 2 Diabetes During Therapy Consisting of Oral Agent(s) Plus Twice-Daily Insulin Lispro Low Mixture or Once-Daily Insulin Glargine Completed NCT00551538 Phase 4 Lispro mix 75/25;Glargine

Search NIH Clinical Center for Acute Contagious Conjunctivitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Cromolyn Sodium
Oxymetazoline hydrochloride
prednisolone acetate
Prednisolone sodium phosphate
prednisolone tebutate

Genetic Tests for Acute Contagious Conjunctivitis

Anatomical Context for Acute Contagious Conjunctivitis

MalaCards organs/tissues related to Acute Contagious Conjunctivitis:

Eye, Bone, Liver, Skin, Brain, Prostate, Spinal Cord

Publications for Acute Contagious Conjunctivitis

Articles related to Acute Contagious Conjunctivitis:

(show top 50) (show all 80)
# Title Authors PMID Year
Skin and eye protection against ultraviolet C from ultraviolet germicidal irradiation devices during the COVID-19 pandemic. 42
33259055 2021
The efficacy and safety of Yuxingcao eye drops in the treatment of COVID-19 conjunctivitis: A protocol for a systematic review. 42
33285684 2020
COVID-19 Associated Multisystem Inflammatory Syndrome: A Systematic Review and Meta-analysis. 42
33463127 2020
Donskoy cats as a new model of oculocutaneous albinism with the identification of a splice-site variant in Hermansky-Pudlak Syndrome 5 gene. 61
32558164 2020
Communicating the risk of contracting Zika virus to low income underserved pregnant Latinas: A clinic-based study. 61
33216763 2020
Tear Film Amphiphilic and Anti-Inflammatory Lipids in Bovine Pink Eye. 61
30469369 2018
The role of lipooligosaccharide in the biological activity of Moraxella bovis strains Epp63, Mb25 and L183/2, and isolation of capsular polysaccharide from L183/2. 61
30032028 2018
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis. 61
29960036 2018
Orbital Inflammatory Syndrome Secondary to Flea Bite. 61
29659432 2018
Co-delivery of timolol and hyaluronic acid from semi-circular ring-implanted contact lenses for the treatment of glaucoma: in vitro and in vivo evaluation. 61
29708242 2018
Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management. 61
29380707 2018
Anisocoria Secondary to Anticholinergic Mydriasis from Homeopathic Pink Eye Relief Drops. 61
29042447 2017
A Rare Case of Tubulointerstitial Nephritis and Uveitis Syndrome Treated with a Multi-Specialty Approach. 61
27867184 2016
Surveillance Tools Emerging From Search Engines and Social Media Data for Determining Eye Disease Patterns. 61
27416554 2016
Effect of "Pink Eye" Label on Parents' Intent to Use Antibiotics and Perceived Contagiousness. 61
26294761 2016
[Emergencies in ophthalmology]. 61
26242419 2015
Elucidation of the structure of the oligosaccharide from wild type Moraxella bovis Epp63 lipooligosaccharide. 61
24632213 2014
Pink eye and discharge for 18 months. 61
23914790 2013
Prevalence, molecular diagnosis and treatment of Mycoplasma conjunctivae isolated from infectious keratoconjunctivitis affected Lohi sheep maintained at Livestock Experiment Station, Bahadurnagar, Okara, Pakistan. 61
23135981 2013
Nurse management of 'same day' consultation for patients with minor illnesses: results of an extended programme in primary care in Catalonia. 61
21762208 2011
Impacts of flood on health: epidemiologic evidence from Hanoi, Vietnam. 61
21866222 2011
Frequency and seasonal variation of ophthalmology-related internet searches. 61
20436544 2010
A 6-year-old girl with 'pink eye' for several months. 61
20506977 2010
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. 61
20463787 2010
Patient information. Pink eye: what you should know. 61
20112458 2010
Impact of retail medicine on standard costs in primary care: a semiparametric analysis. 61
20038259 2009
Mathematical modelling of epidemics under specific regard of adenoviral keratoconjunctivitis. 61
18952517 2008
Mutation analysis in a family with oculocutaneous albinism manifesting in the same generation of three branches. 61
17960121 2007
Clinical features of bacterial conjunctivitis in children. 61
17119185 2007
Self-medicated over the counter ophthalmic solutions in central Bangkok. 61
16623050 2005
The rat pink-eyed dilution (p) mutation: an identical intragenic deletion in pink-eye dilute-coat strains and several Wistar-derived albino strains. 61
16245028 2005
Mosaic supernumerary inv dup(15) chromosome with four copies of the P gene in a boy with pigmentary dysplasia. 61
15054844 2004
Genetic traits of the mosquito Anopheles gambiae: red stripe, frizzled, and homochromy1. 61
12816963 2003
Physical and linkage mapping of the porcine pink-eye dilution gene ( OCA2 ). 61
12354157 2002
P gene as an inherited biomarker of human eye color. 61
12163334 2002
Mosaic: a position-effect variegation eye-color mutant in the mosquito Anopheles gambiae. 61
10768126 2000
DNA organization and length polymorphism at the 2L telomeric region of Anopheles gambiae. 61
9459432 1998
TM rats: a model for platelet storage pool deficiency. 61
9250486 1997
A genetic study of a melanization response to Sephadex beads in Plasmodium-refractory and -susceptible strains of Anopheles gambiae. 61
9158056 1997
The bacillus of acute conjunctival catarrh, or 'pink eye'. 1886. 61
8953986 1996
Observations on the efficacy of mass treatment by subconjunctival penicillin injection for the control of an outbreak of infectious bovine keratoconjunctivitis. 61
16031917 1996
An integrated genetic map of the African human malaria vector mosquito, Anopheles gambiae. 61
8725240 1996
Assignment of genes coding for brown eye colour (BEY2) and brown hair colour (HCL3) on chromosome 15q. 61
8875191 1996
Eye pigments in wild-type and eye-color mutant strains of the African malaria vector Anopheles gambiae. 61
7560874 1995
Differential behavioral outcomes in the sciatic cryoneurolysis model of neuropathic pain in rats. 61
7816482 1994
Identification of Moraxella bovis and related species from calves with IBK and goats by qualitative genetic transformation assay. 61
7839756 1994
[Pink eye in the tropics]. 61
8196519 1994
Comparison of type I and type II Chlamydia psittaci strains infecting koalas (Phascolarctos cinereus). 61
8296453 1993
Pink-eyed dilution, a coat color mutation in the Japanese field vole (Microtus montebelli). 61
1915604 1991
Establishment of the mouse chromosome 7 region with homology to the myotonic dystrophy region of human chromosome 19q. 61
1970795 1990

Variations for Acute Contagious Conjunctivitis

Expression for Acute Contagious Conjunctivitis

Search GEO for disease gene expression data for Acute Contagious Conjunctivitis.

Pathways for Acute Contagious Conjunctivitis

Pathways related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.62 TYRP1 TYR SLC45A2 OCA2

GO Terms for Acute Contagious Conjunctivitis

Cellular components related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome membrane GO:0033162 8.92 TYRP1 TYR SLC45A2 OCA2

Biological processes related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanocyte differentiation GO:0030318 9.32 TYRP1 OCA2
2 developmental pigmentation GO:0048066 9.26 SLC45A2 OCA2
3 pigmentation GO:0043473 9.26 TYRP1 TYR OCA2 HPS5
4 eye pigment biosynthetic process GO:0006726 9.16 TYR OCA2
5 melanin biosynthetic process GO:0042438 8.92 TYRP1 TYR SLC45A2 OCA2

Molecular functions related to Acute Contagious Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase inhibitor activity GO:0004869 8.96 CST9L CST9
2 monophenol monooxygenase activity GO:0004503 8.62 TYRP1 TYR

Sources for Acute Contagious Conjunctivitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....